{"entity":{"id":"muc1","kind":"target","name":"MUC1 (mucin-1)","aka":["Mucin-1","Mucin 1","CD227"],"tldr":"MUC1 is a protein found on cells that line organs. Different fragments expose different binding sites, so a positive test does not tell us what a treatment will recognise.","summary":"MUC1 encodes a cell-surface-associated mucin with an extracellular repeat region and a membrane-associated portion containing a signalling tail. Whole-protein expression, a particular cleavage product and the epitope recognised by a binder are different measurements.\n\nMahanta and colleagues used MUC1* for membrane-anchored cleavage products while noting uncertainty about the precise cleavage sites. Their antibody recognised a membrane-proximal extracellular region rather than the long tandem repeats. The study also found MUC1* staining on the luminal surface of noncancerous fallopian-tube epithelium. Neither generic MUC1 RNA nor a different antibody stain proves that the proposed receptor recognises the intended fragment or spares healthy tissue.","asOf":"2026-11-12","links":[{"label":"HGNC:7508, MUC1","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7508"},{"label":"UniProt P15941, reviewed human mucin-1","url":"https://www.uniprot.org/uniprotkb/P15941/entry"},{"label":"Mahanta et al., 2008: MUC1 cleavage-product study","url":"https://pubmed.ncbi.nlm.nih.gov/18446242/"}],"tags":[],"related":["on-target-off-tumour-toxicity","car-t","tumor-associated-antigen"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Specify the actual extracellular epitope, cleavage or glycosylation context, binder and tissue. In the 2008 study, antibodies against the tandem repeats and the membrane-associated cleavage product gave different staining patterns. That mechanistic and tissue work was not a CAR-T clinical trial or evidence that every MUC1-directed design is tumour-exclusive."],"symbol":"MUC1","role":["antigen"],"sources":[],"specificitySources":[],"hgnc":"HGNC:7508","ensembl":"ENSG00000185499","uniprot":"P15941","entrez":"4582","biology":"The extracellular alpha subunit can support adhesion or oppose it, while the beta-subunit cytoplasmic region participates in signalling. Tissue location, cleavage and epitope exposure affect what an antibody or engineered receptor can recognise.","whereFound":[],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/muc1/","neighbours":{"term":[{"id":"on-target-off-tumour-toxicity","kind":"term","name":"On-target, off-tumour toxicity and off-target cross-reactivity","route":"/terms/on-target-off-tumour-toxicity/"},{"id":"tumor-associated-antigen","kind":"term","name":"Tumour-associated antigen (TAA)","route":"/terms/tumor-associated-antigen/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}]}}